1. Multistage malaria shot shows mid-term protection in Malian adults – but transmission benefits still unproven In this randomized, double blind trial from peri urban Mali, 34 healthy adults (18–50 years) with relatively low prior malaria exposure received three intramuscular doses (0, 1, 2 months) of the multistage subunit vaccine ProC6C AlOH/Matrix M (100 µg ProC6C + ~50 µg Matrix M) or rabies vaccine control, followed 12 weeks later by intradermal controlled human malaria infection (CHMI) with 22 500 PfSPZ (NF54). ProC6C incorporates PfCSP NANP, and NVDP repeats plus Pfs230 and Pfs48/45 epitopes. Among 32 challenged participants (16 per group), 6/16 vaccinees versus 13/16 controls developed PCR-detected parasitemia by day 28, corresponding to 76% vaccine efficacy by time to event analysis (Cox) and 54% efficacy by proportional (risk ratio) analysis (95% CI 9–77, p=0.029). Median prepatent period was delayed from 12 to 14 days in vaccinees (p=0.049). The vaccine was more reactogenic...
🔒 Premium Content - For Free
Unlock this content by becoming a Global Health Press subscriber. Join for exclusive articles, expert research, and valuable insights!
